As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Eli Lilly's sales growth is coming short of expectations ... We could point out that tirzepatide, the active ingredient in ...

According to Eli Lilly: Zepbound is available for people without ... Zepbound for people whose doctors have prescribed it off-label. Off-label means that a doctor prescribes a medication for ...

Lilly claims the single-dose versions ... In a statement, Ro said it will make Zepbound available as a treatment option with an on-label prescription from a Ro-affiliated provider that will ...

So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Eli Lilly unexpectedly lowered its full-year ... but is commonly used off-label for weight loss. Zepbound has the same active ingredient, tirzepatide, but is approved for weight loss in obese ...

Over the past six months, Eli Lilly (NYSE ... the active ingredient in Mounjaro and Zepbound, is still undergoing many clinical trials and should earn key label expansions. Last year, the medicine ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound ...